FDA Approves Reblozyl (luspatercept-aamt) to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 3, 2020-- Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news